Can We Predict Heart Attacks Years Before They Happen? | The Future of Cardio Genomics
Why It Matters
Predictive, multi‑omics biomarkers could transform cardiovascular prevention, enabling earlier, personalized interventions and reducing the global burden of heart disease.
Key Takeaways
- •Malta's small population enables rapid, comprehensive multi‑omics data collection.
- •Target MI aims to create predictive biomarkers for 5‑10 year heart attacks.
- •Integrating genomics, proteomics, and metabolomics improves risk stratification beyond traditional scores.
- •Early protein biomarker test will be validated with Dutch cohort collaboration.
- •Project secures €8.5 million, retaining Maltese scientists and boosting EU research impact.
Summary
The video introduces Target MI, a €4 million EU‑funded initiative led by Professor Stephanie Bassina Wittinger in Malta, that seeks to predict heart attacks years before they occur using a multi‑omics approach. By leveraging the island’s compact population, the team assembled a richly detailed cohort of over 1,000 volunteers, collecting whole‑genome sequences, 20,000 blood‑based molecular measurements, and more than 700 lifestyle and clinical variables, then re‑contacting participants a decade later for outcomes. Key insights include the project's high‑throughput pipeline that processes blood samples within an hour, the integration of genomics, transcriptomics, proteomics and metabolomics, and the emphasis on gene‑environment interactions that can amplify or mitigate genetic risk. The data set enables the identification of novel drug targets and the development of a protein‑based biomarker panel that outperforms conventional risk scores. Professor Wittinger highlights that genetics alone cannot predict cardiovascular events; instead, combining molecular layers with lifestyle factors yields actionable patterns. The team is already testing a protein signature against a Dutch cohort at Leiden University Medical Center, and the project has secured over €8.5 million in funding, helping retain Maltese talent and positioning the island as a European research hub. If successful, Target MI could deliver a clinical test that flags individuals at high risk of specific heart‑attack subtypes years in advance, guiding personalized prevention strategies and accelerating drug development. The broader impact extends to pharmaceutical pipelines, healthcare cost reduction, and a model for clinician‑researcher collaboration across Europe.
Comments
Want to join the conversation?
Loading comments...